All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis

Respiratory Investigation

Volumn 53, Issue 5, 2015, Pages 232-241

  Ogura, Takashi ^a   Azuma, Arata ^b   Inoue, Yoshikazu ^c   Taniguchi, Hiroyuki ^d   Chida, Kingo ^e   Bando, Masashi ^f   Niimi, Yuka ^g   Kakutani, Shinichi ^g   Suga, Moritaka ^h   Sugiyama, Yukihiko ^f   Kudoh, Shoji ⁱ   Nukiwa, Toshihiro ⁱ  

^a Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d TOSEI GENERAL HOSPITAL   (Japan)

^e Internal Medicine Hamamatsu Toyooka Hospital   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g SHIONOGI AND CO LTD   (Japan)

^h SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

ⁱ FUKUJUJI HOSPITAL   (Japan)

Author keywords

Idiopathic pulmonary fibrosis; Pirfenidone; Post marketing surveillance; Safety

Indexed keywords

C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; PIRFENIDONE; PYRIDONE DERIVATIVE;

ABDOMINAL DISEASE; ADULT; AGED; ARTICLE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FEMALE; FIBROSING ALVEOLITIS; HUMAN; JAPAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MORTALITY; NAUSEA; OBSERVATIONAL STUDY; PHOTOSENSITIVITY; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; PRURITUS; RASH; RISK ASSESSMENT; SOMNOLENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VITAL CAPACITY; VOMITING; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PYRIDONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84940901206     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.06.001     Document Type: Article

References (29)

1. Ley B., Collard H.R., King T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
2. Raghu G., Collard H.R., Egan J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
3. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
4. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
5. Taniguchi H., Ebina M., Kondoh Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
6. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
7. Spagnolo P., Del Giovane C., Luppi F., et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010, 9.
8. King T.E., Bradford W.Z., Castro-Bernardini S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
9. Raghu G., Johnson W.C., Lockhart D., et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159:1061-1069.
10. Nagai S., Hamada K., Shigematsu M., et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002, 41:1118-1123.
11. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
12. Japanese Respiratory Society[U+05F3]s Committee formulating diagnosis and treatment guideline for diffuse lung diseases. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias 2011, Nankodo, Tokyo, .p. 111-3. 2nd ed.
13. Azuma A., Taguchi Y., Ogura T., et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011, 12:143-153.
14. Fletcher C.M. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med 1952, 45:577-584.
15. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001, 11:9-21.
16. Siddiqui O., Hung H.M., O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009, 19:227-246.
17. Zappala C.J., Latsi P.I., Nicholson A.G., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:830-835.
18. Taniguchi H., Kondoh Y., Ebina M., et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011, 12:93-101.
19. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams and Wilkins, Philadelphia, PA. 2nd ed.
20. Valeyre D., Albera C., Bradford W.Z., et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014, 19:740-747.
21. Arai T., Inoue Y., Sasaki Y., et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014, 52:136-143.
22. Okuda R., Hagiwara E., Baba T., et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013, 107:1431-1437.
23. Bonella F., Wessendorf T.E., Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr 2013, 138:518-523. [in German].
24. Collard H.R., King T.E., Bartelson B.B., et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
25. King T.E., Safrin S., Starko K.M., et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005, 127:171-177.
26. Loeh B., Drakopanagiotakis F., Bandelli G.P., et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015, 191:110-113.
27. Okazaki A., Ohkura N., Fujimura M., et al. Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther 2013, 5:603-608.
28. Chiba H, Natsuizaka M, Shiratori M, et al. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido. The annual report by study group of ministry of health and welfare for diffuse lung diseases; 2012. p. 125-34.
29. Ley B., Ryerson C.J., Vittinghoff E., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.